Sanguinarine

Sanguinarine
Product Name Sanguinarine
CAS No.: 2447-54-3
Catalog No.: CFN98259
Molecular Formula: C20H14NO4
Molecular Weight: 332.3 g/mol
Purity: >=98%
Type of Compound: Alkaloids
Physical Desc.: Powder
Targets: Akt | NF-kB | ROS | Bcl-2/Bax | Caspase | HIF | PARP | HO-1 | Nrf2 | ERK | Calcium Channel | ATPase | DNA/RNA Synthesis
Source: The herbs of Chelidonium majus
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price: $30/20mg
Sanguinarine possesses anticancer, antimicrobial, anti-inflammatory, and antioxidant properties, it has therapeutic potential in preventing the neurodegenerative diseases, it may be used to develop a potential therapeutic drug for treating cardiac remodeling and heart failure and shows protective effects on teeth and alveolar bone health. Sanguinarine can inhibit osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-κB and ERK signaling pathways, and can protect against cardiac hypertrophy and fibrosis via inhibiting NF-κB activation.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Braz J Biol.2023, 82:e266573.
  • Foods.2022, 11(12):1773.
  • Front Pharmacol.2019, 10:1025
  • J. of Agricultural Science2015, 1916-9760
  • Food Chem.2019, 275:746-753
  • Asian J of Pharmaceutical&Clinical 2018, 11(2)
  • Archives of Biological sciences2022, 00:21-21
  • BMC Complement Altern Med.2018, 18(1):221
  • Evid Based Complement Alternat Med.2022, 2022:1307173.
  • Molecules.2019, 24(21):E3834
  • Angoline

    Catalog No: CFN91469
    CAS No: 21080-31-9
    Price: Inquiry(manager@chemfaces.com)
    6-Ethoxydihydrochelerythrine

    Catalog No: CFN91468
    CAS No: 7441-89-0
    Price: Inquiry(manager@chemfaces.com)
    Norsanguinarine

    Catalog No: CFN92811
    CAS No: 522-30-5
    Price: Inquiry(manager@chemfaces.com)
    Oxysanguinarine

    Catalog No: CFN91002
    CAS No: 548-30-1
    Price: $268/10mg
    Chelerythrine

    Catalog No: CFN98449
    CAS No: 34316-15-9
    Price: $40/20mg
    Bocconoline

    Catalog No: CFN95373
    CAS No: 32906-88-0
    Price: $413/5mg
    6-Acetonyl-N-methyl-dihydrodecarine

    Catalog No: CFN99367
    CAS No: 1253740-09-8
    Price: Inquiry(manager@chemfaces.com)
    6-Acetonyldihydrochelerythrine

    Catalog No: CFN98233
    CAS No: 22864-92-2
    Price: Inquiry(manager@chemfaces.com)
    8-Acetonyldihydrosanguinarine

    Catalog No: CFN98608
    CAS No: 37687-34-6
    Price: Inquiry(manager@chemfaces.com)
    8-Acetonyldihydroavicine

    Catalog No: CFN92338
    CAS No: 348098-59-9
    Price: Inquiry(manager@chemfaces.com)
    Clin Cancer Res. 2000 Apr;6(4):1524-8.
    Differential antiproliferative and apoptotic response of sanguinarine for cancer cells versus normal cells.[Pubmed: 10778985]
    Sanguinarine, derived from the root of Sanguinaria canadendid, has been shown to possess antimicrobial, anti-inflammatory, and antioxidant properties. Here we compared the antiproliferative and apoptotic potential of Sanguinarine against human epidermoid carcinoma (A431) cells and normal human epidermal keratinocytes (NHEKs).
    METHODS AND RESULTS:
    Sanguinarine treatment was found to result in a dose-dependent decrease in the viability of A431 cells as well as NHEKs albeit at different levels because Sanguinarine-mediated loss of viability occurred at lower doses and was much more pronounced in the A431 carcinoma cells than in the normal keratinocytes. DNA ladder assay demonstrated that compared to vehicle-treated control, Sanguinarine treatment of A431 cells resulted in an induction of apoptosis at 1-, 2-, and 5-microM doses. Sanguinarine treatment did not result in the formation of a DNA ladder in NHEKs, even at the very high dose of 10 microM. The induction of apoptosis by Sanguinarine was also evident by confocal microscopy after labeling the cells with annexin V. This method also identified necrotic cells, and Sanguinarine treatment also resulted in the necrosis of A431 cells. The NHEKs showed exclusively necrotic staining at high doses (2 and 5 microM). We also explored the possibility of cell cycle perturbation by Sanguinarine in A431 cells. The DNA cell cycle analysis revealed that Sanguinarine treatment did not significantly affect the distribution of cells among the different phases of the cell cycle in A431 cells.
    CONCLUSIONS:
    We suggest that Sanguinarine could be developed as an anticancer drug.
    Oncotarget. 2015 Apr 30;6(12):10335-49.
    Molecular signatures of sanguinarine in human pancreatic cancer cells: A large scale label-free comparative proteomics approach.[Pubmed: 25929337]
    Pancreatic cancer remains one of the most lethal of all human malignancies with its incidence nearly equaling its mortality rate. Therefore, it's crucial to identify newer mechanism-based agents and targets to effectively manage pancreatic cancer. Plant-derived agents/drugs have historically been useful in cancer therapeutics. Sanguinarine is a plant alkaloid with anti-proliferative effects against cancers, including pancreatic cancer. This study was designed to determine the mechanism of Sanguinarine's effects in pancreatic cancer with a hope to obtain useful information to improve the therapeutic options for the management of this neoplasm.
    METHODS AND RESULTS:
    We employed a quantitative proteomics approach to define the mechanism of Sanguinarine's effects in human pancreatic cancer cells. Proteins from control and Sanguinarine-treated pancreatic cancer cells were digested with trypsin, run by nano-LC/MS/MS, and identified with the help of Swiss-Prot database. Results from replicate injections were processed with the SIEVE software to identify proteins with differential expression. We identified 37 differentially expressed proteins (from a total of 3107), which are known to be involved in variety of cellular processes. Four of these proteins (IL33, CUL5, GPS1 and DUSP4) appear to occupy regulatory nodes in key pathways. Further validation by qRT-PCR and immunoblot analyses demonstrated that the dual specificity phosphatase-4 (DUSP4) was significantly upregulated by Sanguinarine in BxPC-3 and MIA PaCa-2 cells. Sanguinarine treatment also caused down-regulation of HIF1α and PCNA, and increased cleavage of PARP and Caspase-7.
    CONCLUSIONS:
    Taken together, Sanguinarine appears to have pleotropic effects, as it modulates multiple key signaling pathways, supporting the potential usefulness of Sanguinarine against pancreatic cancer.
    Environ Toxicol Pharmacol. 2014 Nov;38(3):701-10.
    Involvement of heme oxygenase-1 in neuroprotection by sanguinarine against glutamate-triggered apoptosis in HT22 neuronal cells.[Pubmed: 25299846]
    Sanguinarine is a natural compound isolated from the roots of Macleaya cordata and M. microcarpa, has been reported to possess several biological activities such as anti-inflammatory and anti-oxidant effects.
    METHODS AND RESULTS:
    In the present study, we demonstrated that Sanguinarine markedly induces the expression of HO-1 which leads to a neuroprotective response in mouse hippocampus-derived neuronal HT22 cells from apoptotic cell death induced by glutamate. Sanguinarine significantly attenuated the loss of mitochondrial function and membrane integrity associated with glutamate-induced neurotoxicity. Sanguinarine protected against glutamate-induced neurotoxicity through inhibition of HT22 cell apoptosis. JC-1 staining, which is a well-established measure of mitochondrial damage, was decreased after treatment with Sanguinarine in glutamate-challenged HT22cells. In addition, Sanguinarine diminished the intracellular accumulation of ROS and Ca(2+). Sanguinarine also induced HO-1, NQO-1 expression via activation of Nrf2. Additionally, we found that si RNA mediated knock-down of Nrf2 or HO-1 significantly inhibited Sanguinarine-induced neuroprotective response.
    CONCLUSIONS:
    These findings revealed the therapeutic potential of Sanguinarine in preventing the neurodegenerative diseases.
    Oncotarget . 2016 Apr 19;7(16):22355-67.
    Noninvasive bioluminescence imaging of the dynamics of sanguinarine induced apoptosis via activation of reactive oxygen species[Pubmed: 26968950]
    Abstract Most chemotherapeutic drugs exert their anti-tumor effects primarily by triggering a final pathway leading to apoptosis. Noninvasive imaging of apoptotic events in preclinical models would greatly facilitate the development of apoptosis-inducing compounds and evaluation of their therapeutic efficacy. Here we employed a cyclic firefly luciferase (cFluc) reporter to screen potential pro-apoptotic compounds from a number of natural agents. We demonstrated that Sanguinarine (SANG) could induce apoptosis in a dose- and time-dependent manner in UM-SCC-22B head and neck cancer cells. Moreover, SANG-induced apoptosis was associated with the generation of reactive oxygen species (ROS) and activation of c-Jun-N-terminal kinase (JNK) and nuclear factor-kappaB (NF-κB) signal pathways. After intravenous administration with SANG in 22B-cFluc xenograft models, a dramatic increase of luminescence signal can be detected as early as 48 h post-treatment, as revealed by longitudinal bioluminescence imaging in vivo. Remarkable apoptotic cells reflected from ex vivo TUNEL staining confirmed the imaging results. Importantly, SANG treatment caused distinct tumor growth retardation in mice compared with the vehicle-treated group. Taken together, our results showed that SANG is a candidate anti-tumor drug and noninvasive imaging of apoptosis using cFluc reporter could provide a valuable tool for drug development and therapeutic efficacy evaluation. Keywords: apoptosis; bioluminescence imaging; luciferase reporter; Sanguinarine; therapeutic efficacy.
    Mol Med Rep. 2014 Jul;10(1):211-6.
    Sanguinarine protects against pressure overload‑induced cardiac remodeling via inhibition of nuclear factor-κB activation.[Pubmed: 24804701]
    Cardiac remodeling is a major determinant of heart failure characterized by cardiac hypertrophy and fibrosis. Sanguinarine exerts widespread pharmacological effects, including antitumor and anti‑inflammatory responses. In the present study, the effect of Sanguinarine on cardiac hypertrophy, fibrosis and heart function was determined using the model induced by aortic banding (AB) in mice.
    METHODS AND RESULTS:
    AB surgery and sham surgery were performed on male wild‑type C57 mice, aged 8‑10 weeks, with or without administration of Sanguinarine from one week after surgery for an additional seven weeks. Sanguinarine protected against the cardiac hypertrophy, fibrosis and dysfunction induced by AB, as assessed by the heart weight/body weight, lung weight/body weight and heart weight/tibia length ratios, echocardiographic and hemodynamic parameters, histological analysis, and the gene expression levels of hypertrophic and fibrotic markers. The inhibitory effect of Sanguinarine on cardiac remodeling was mediated by inhibiting nuclear factor (NF)‑κB signaling pathway activation.
    CONCLUSIONS:
    The findings indicated that Sanguinarine protected against cardiac hypertrophy and fibrosis via inhibiting NF‑κB activation. These findings may be used to develop a potential therapeutic drug for treating cardiac remodeling and heart failure.
    Biochem Biophys Res Commun. 2013 Jan 18;430(3):951-6.
    Sanguinarine inhibits osteoclast formation and bone resorption via suppressing RANKL-induced activation of NF-κB and ERK signaling pathways.[Pubmed: 23261473 ]
    Sanguinarine is a natural plant extract that has been supplemented in a number of gingival health products to suppress the growth of dental plaque. However, whether Sanguinarine has any effect on teeth and alveolar bone health is still unclear.
    METHODS AND RESULTS:
    In this study, we demonstrated for the first time that Sanguinarine could suppress osteoclastic bone resorption and osteoclast formation in a dose-dependent manner. Sanguinarine diminished the expression of osteoclast marker genes, including TRAP, cathepsin K, calcitonin receptor, DC-STAMP, V-ATPase d2, NFATc1 and c-fos. Further investigation revealed that Sanguinarine attenuated RANKL-mediated IκBα phosphorylation and degradation, leading to the impairment of NF-κB signaling pathway during osteoclast differentiation. In addition, Sanguinarine also affected the ERK signaling pathway by inhibiting RANKL-induced ERK phosphorylation.
    CONCLUSIONS:
    Collectively, this study suggested that Sanguinarine has protective effects on teeth and alveolar bone health.
    Phytochemistry. 1997 Jan;44(2):257-66.
    Biochemical activities of berberine, palmatine and sanguinarine mediating chemical defence against microorganisms and herbivores.[Pubmed: 9004542]
    The alkaloids berberine, palmatine and Sanguinarine are toxic to insects and vertebrates and inhibit the multiplication of bacteria, fungi and viruses. Biochemical properties which may contribute to these allelochemical activities were analysed. Acetylcholine esterase, butyrylcholinesterase, choline acetyl transferase, alpha 1- and alpha 2-adrenergic, nicotinergic, muscarinergic and serotonin2 receptors were substantially affected. Sanguinarine appears to be the most effective inhibitor of choline acetyl-transferase (IC50 284 nM), while the protoberberines were inactive at this target. Berberine and palmatine were most active at the alpha 2-receptor (binding with IC50 476 and 956 nM, respectively). Furthermore, berberine and Sanguinarine intercalate DNA, inhibit DNA synthesis and reverse transcriptase. In addition, Sanguinarine (but not berberine) affects membrane permeability and berberine protein biosynthesis. In consequence, these biochemical activities may mediate chemical defence against microorganisms, viruses and herbivores in the plants producing these alkaloids.
    J Pharmacol Sci. 2015 Jan;127(1):135-44.
    BCL2 promotor methylation and miR-15a/16-1 upregulation is associated with sanguinarine-induced apoptotic death in rat HSC-T6 cells[Pubmed: 25704029]
    Previous studies show that several pathways are involved in Sanguinarine-induced apoptotic cell death, including AKT downregulation, inhibition of NF-kB activation, mediation of ROS production, downregulation of anti-apoptosis proteins XIAP and cIAP-1, upregulation of BAX, and downregulation of BCL2.
    METHODS AND RESULTS:
    Sanguinarine-induced rat hepatic stellate T6 cells (HSC-T6 cells) apoptosis was correlated with the generation of increased ROS, which was followed by the activation of caspase-8 (-3, -6, and -9), and the decreasing in the miltochondrial membrane potential (MMP) and the down-regulation of anti-apoptotic protein Bcl-2. We showed that Sanguinarine-induced down regulation of BCL2 was associated with the increased methylation rate of BCL2 promotor district and the increased expression of miR-15a/16-1. HSC-T6 cells treatment with 5-Aza-2'-deoxycytidine (5'-Aza-CdR) impeded Sanguinarine-induced BCL2 promotor district methylation and recovered BCL2's expression. Over expression of BCL2 using pEGFP-N1 vector decreased Sanguinarine-induced HSC-T6 cells apoptotic death significantly but not completely.
    CONCLUSIONS:
    These observations clearly showed that BCL2 down regulation was associated with its promoter methylation and miR-15a/16-1 upregulation in Sanguinarine-induced Rat HSC-T6 cells.
    Kakkalide

    Catalog No: CFN95052
    CAS No: 58274-56-9
    Price: $260/10mg
    Parvisoflavanone

    Catalog No: CFN95077
    CAS No: 49776-79-6
    Price: $413/5mg
    Rhamnetin 3-galactoside

    Catalog No: CFN95116
    CAS No: 62858-07-5
    Price: $318/5mg
    Phyllanthusiin C

    Catalog No: CFN95260
    CAS No: 142674-52-0
    Price: $318/5mg
    Isoedultin

    Catalog No: CFN95273
    CAS No: 43043-08-9
    Price: $318/5mg
    New compound 14

    Catalog No: CFN95381
    CAS No: N/A
    Price: $413/5mg
    3-Hydroxymollugin

    Catalog No: CFN95424
    CAS No: 154706-45-3
    Price: $368/5mg
    Campneoside II

    Catalog No: CFN95498
    CAS No: 95587-86-3
    Price: $318/10mg
    erythro-Austrobailignan-6

    Catalog No: CFN95501
    CAS No: 114127-24-1
    Price: $318/10mg
    Clinopodic acid E

    Catalog No: CFN95595
    CAS No: 159736-38-6
    Price: $318/5mg